Promising combo aims to shrink deadly eye cancer tumors

NCT ID NCT06121180

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two drugs, cemiplimab and ziv-aflibercept, can shrink or stop the growth of metastatic uveal melanoma, a rare eye cancer that has spread. About 32 adults with this condition will receive the combination treatment. The goal is to see if the drugs work better together than alone, while monitoring safety and tumor response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic melanoma uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC UVEAL MELANOMA

Contacts and locations

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Northwell Health Center for Advanced Medicine
RECRUITING

New Hyde Park, New York, 11042, United States
The Angeles Clinic and Research Institute
RECRUITING

Los Angeles, California, 90025, United States
University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.